HK Stock MarketDetailed Quotes

02257 SIRNAOMICS-B

Watchlist
  • 2.600
  • -0.200-7.14%
Market Closed Nov 22 16:08 CST
227.86MMarket Cap-356P/E (TTM)
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    According to Dr. Patrick Lu, CEO of Sirnaomics, Dr. Lebel's promotion will enrich Sirnaomics' ability to advance its clinical-stage and pre-clinical RNAi-based treatments. Dr. Lebel himself expressed commitment to lead Sirnaomics' RNAi pipeline through clinical development to the commercial stage.
    Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase II clinical outcomes in oncology for an RNAi therapeutic for its cor...
    Sirnaomics 2022 Annual Results Investor Presentation
    Mar 29 08:00
    Replay
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data